The United States Food and Drug Administration (USFDA) has conducted an inspection at the manufacturing facility of InvaGen Pharmaceuticals Inc., a wholly owned subsidiary of Cipla, located in Central Islip, Long Island, New York, USA, from July 13, 2026 to July 17, 2026 (EDT). The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection.
On conclusion of the inspection, the company has received one inspectional observation in Form 483. The company will work closely with the USFDA and is committed to address this comprehensively within stipulated time.
Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
